Behrndt-Eriksen Mads Nikolaj 4

What Happened Mads Nikolaj Behrndt-Eriksen, Hemab Therapeutics (COAG) Chief Financial Officer and General Manager, received two equity awards: a warrant granted Jan 29, 2026 for 195,206 underlying shares and an option granted Apr 30, 2026 for 49,016 underlying shares. Both awards are reported as derivative grants at $0.00 exercise/purchase price (code A) and are subject to multi-year vesting schedules rather than an immediate cash purchase or sale.

Key Details

• Transactions: 195,206 shares (warrant) on 2026-01-29; 49,016 shares (option) on 2026-04-30. Both reported as grants (derivative) at $0.00.
• Total underlying shares granted: 244,222.
• Vesting (per filing footnotes):
  • Jan 29 warrant: vests over 4 years — 25% on Jan 1, 2027, remainder in equal monthly installments thereafter (F1).
  • Apr 30 option: vests over 4 years in equal monthly installments from May 1, 2026 through May 1, 2030 (F2).
• Filing date: May 4, 2026. The Jan 29 grant was reported late relative to the usual two-business-day Form 4 deadline; the Apr 30 grant was reported on May 4, which appears to meet the two-business-day window.
• Shares owned after the transactions: not specified in the filing.
• Remarks on form: Insider role listed as Chief Financial Officer and General Manager.

Context These entries are grants of derivative awards (warrants/options) that vest over time and do not represent immediate purchases or sales. Such awards are commonly used for executive compensation and do not by themselves indicate a buying or selling signal. No exercises or sales were reported here; the underlying shares will be deliverable only as they vest per the schedules above.